Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05528588 · ClinicalTrials.gov registry record · Phase 2
Furoscix in Heart Failure Patients With Diuretic Resistance
A Phase 2 study, sponsored by University of Texas Southwestern Medical Center.
- Completed
- Registry status
- Phase 2
- Development phase
- 70
- Enrollment target
NCT05528588 is a Phase 2 study that has completed, run by University of Texas Southwestern Medical Center. The registered enrollment target is 70 participants.
The verdict
NCT05528588, a Phase 2 study, has completed, sponsored by University of Texas Southwestern Medical Center.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 70 participants
- Enrollment target
Study Summary
This will be a randomized, open-label pilot study of 70 patients with and without diuretic resistance who were recently admitted and discharged for acute decompensated heart failure with and oral diuretic regimen testing whether Furoscix is more effective at achieving post-discharge outpatient diuresis than standard of care. Diuretic resistance will be identified using the BAN-ADHF (BUN, creAtinine, NP-levels, Age, Diabetes and DBP, HF hospitalization, and atrial Fibrillation) score which has been integrated into the electronic health record. The score is integer-based with a score of ≥ 12 indicating diuretic resistance with high likelihood of poor outcomes. The primary outcome is diuretic efficacy as measured by volume of urine produced 8 hours after treatment and urine sodium levels (assessed hourly or per urination episode within 8 hours of treatment).
Interventions
- COMBINATION_PRODUCT Furoscix
- DRUG Diuretic Therapy
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 70 participants |
| Start Date | 2023-06-02 |
| Est. Completion | 2024-07-01 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05528588
The ClinicalTrials.gov registry entry for NCT05528588 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 70 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Texas Southwestern Medical Center, which has 837 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Furoscix is the first listed.
NCT05528588 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05528588 about?
NCT05528588 is a clinical study titled "Furoscix in Heart Failure Patients With Diuretic Resistance". This will be a randomized, open-label pilot study of 70 patients with and without diuretic resistance who were recently admitted and discharged for acute decompensated heart failure with and oral diuretic regimen testing whether Furoscix is more effective at achieving post-discharge outpatient diure...
What is the current status of trial NCT05528588?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 70 participants. The study started on 2023-06-02. Estimated completion is 2024-07-01.
What interventions are being tested in trial NCT05528588?
The interventions under investigation include: Furoscix (COMBINATION_PRODUCT), Diuretic Therapy (DRUG).
Who is sponsoring clinical trial NCT05528588?
This trial is sponsored by University of Texas Southwestern Medical Center, which has 837 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.